The Role of RAD51C in the Development of Ovarian Cancer: An In Vitro Animal Experiment Study-Reference-Cited by-同舟云学术

The Role of RAD51C in the Development of Ovarian Cancer: An In Vitro Animal Experiment Study

Published:2024-05-20 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Lu Xiaoli¹,Li Xiaying¹,Jiang Junxiu²,Deng Huan³,Lu Chunbin⁴

Affiliation:

1. Zhongshan Sanxiang Hospital

2. Runchun Bioengineering (Guangzhou) Co., Ltd

3. The Fourth Affiliated Hospital of Nanchang University

4. Jinan University

Abstract

Objective: This study aims to investigate the role of the RAD51C gene in the development of ovarian cancer. A lentivirus-based RAD51C interference system was constructed to infect A2780 cells, followed by regular screening and injection of selected cell lines into nude mice. The study also analyzed the differential expression of the RAD51C, VEGF, and NRP-2 proteins. Methods: A2780 cells were cultured, and RAD51C expression was detected. A RAD51C interference vector was constructed and packaged into a lentivirus, which was then used for cell transfection. The transfection efficiency was confirmed using qPCR, and stable cell lines were established by regular screening. A CDX model was created, and tumor formation was observed. Tumor tissues were collected and analyzed for the expression of RAD51C, VEGF, and NRP-2 proteins using Western blotting and immunohistochemistry. Results: qPCR validation demonstrated that the RAD51C lentivirus had the most significant interference effect in the SiRAN285 group. Among the CDX model groups, the Si-RAD51C group exhibited the lowest tumor volume and weight, along with significantly reduced expression of the RAD51C, NRP-2, and VEGF proteins. Conclusion: RAD51C interference lentivirus effectively inhibited the formation of A2780 ovarian cancer cell tumors and suppressed the expression of the RAD51C, NRP-2, and VEGF proteins.

Publisher

Research Square Platform LLC

Reference35 articles.

1. 1. Wen Qin, Wei Xie, Qinglin He, Tianwei Sun, Chaoguo Meng, Kunling,Yuanfu Luo, and Dongmei Yang. MicroRNA-152 inhibits ovarian cancer cell proliferation and migration and may infer improved outcomes in ovarian cancer through targeting FOXP1.Exp Ther Med. 2018 Feb; 15(2): 1672–1679.

2. 2. Muinao T, Deka Boruah HP, Pal M. Diagnostic and Prognostic Biomarkers in ovarian cancer and the potential roles of cancer stem cells - An updated review. Exp Cell Res. 2018 Jan 1;362(1):1–10.

3. 3. Xiao-Li Lu, Si-Sun Liu, Zhen-Fang Xiong Clinical significance of RAD51C and its contribution to ovaria carcinogenesis Int J Clin Exp Pathol 2020;13(1):14–20.

4. 4. ZHAO Meng-ze, LI Feng-zhi, WANG Peng-yin, LI Jian, XU Han-mei. Research Progress of Dual-target Blocking Therapy of PD-L1 and VEGF. China Biotechnology, 2021, 41(9): 71–77.

5. 5. FU Xiaoling, GUO Zhe, XU Jing, TANG Xu, ZENG Hui, SHI Huirong. Effects of miR-424 targeting NRP2 on proliferation, migration and cisplatin sensitivity of cervical cancer cells. Journal of Modern Oncology, 2022, 30(10):1741–1747.